KLK3 and cancer: In this study, over 500 serum samples were screened against the PrCa Biomarker Panel (FLNA, FLNB, KRT19), and this data was combined with age, PSA test results and Gleason score to assess whether this combinatorial approach was better at predicting prostate cancer, high-risk disease versus indolent disease and discriminating between benign prostate hyperplasia and cancer than the PSA test alone.